BioXcel Therapeutics, Inc.
BTAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $14 | $10 | $18 |
| - Cash | $37 | $17 | $31 | $30 |
| + Debt | $92 | $109 | $106 | $103 |
| Enterprise Value | – | $105 | $85 | $91 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -18.3% | -28.6% | -54.1% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 12.2% | 10.8% | 91.7% | -127.3% |
| EBITDA | -$26 | -$15 | -$3 | -$7 |
| % Margin | -27,003.1% | -12,408.3% | -1,895.8% | -1,844.3% |
| Net Income | -$31 | -$19 | -$7 | -$11 |
| % Margin | -31,541.8% | -15,989.2% | -4,317.9% | -2,966.9% |
| EPS Diluted | -2.18 | -2.45 | -1.5 | -3.57 |
| % Growth | 11% | -63.3% | 58% | – |
| Operating Cash Flow | -$19 | -$13 | -$12 | -$15 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$19 | -$13 | -$12 | -$15 |